Invasive Meningococcal Disease in Adolescents and Young Adults

Harrison, Lee H.; Pass, Margaret; Mendelsohn, Aaron B.; Eğri, Mücahit; Rosenstein, Nancy E.; Bustamante, A Aldana; Razeq, Jafar; Roche, Jeffrey C.

doi:10.1001/jama.286.6.694

Cited by 126 publications

(78 citation statements)

References 26 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bu nedenle en kısa sürede ilk doz antibiyoterapinin uygulanması hayati (12). Ayrıca adrenal yetmezliğe (WaterhouseFriderichsen sendromu) yol açan adrenal enfarktüs de hipotansiyon nedeni olabilir (13). Bu olasılık göz önüne alınarak hastamıza tedavide metilprednizolon eklenmişti.…”

Section: Olgu Sunumuunclassified

A Case of High Mortality, Treated with Multidisciplinary Approach in Intensive Care: Meningococcal Meningitis

Küçük¹,

Yılmaz²,

Aydın³

et al. 2018

tybd

View full text Add to dashboard Cite

Section: Olgu Sunumuunclassified

A Case of High Mortality, Treated with Multidisciplinary Approach in Intensive Care: Meningococcal Meningitis

Küçük¹,

Yılmaz²,

Aydın³

et al. 2018

tybd

View full text Add to dashboard Cite

“…1) 24) . A secondary peak of risk, with incidence rates~1-3/100,000 is seen in adolescents and young adults (11-24 years-old) 25) . Recent trends suggest that the population of older adults form a third age cohort at elevated risk for meningococcal disease.…”

Section: Epidemiologymentioning

confidence: 99%

Meningococcal Disease and Quadrivalent MenACWY-CRM Vaccine (Menveo®)

Tsai

2012

Korean J Pediatr Infect Dis

View full text Add to dashboard Cite

® (Novartis Vaccines and Diagnostics), a novel quadrivalent meningococcal conjugate vaccine directed against meningococcal serogroups A, C, W-135 and Y, has been shown to be immunogenic and well tolerated in all age groups and was recently licensed for use in Korea. Recent cases and deaths among military recruits drew public attention to their elevated risk and the Korean government has recommended vaccination of all new military recruits. Many Korean students seek to attend school, university, or language institutes in countries where routine meningococcal vaccination is required -clinicians should be aware of such requirements to ensure that students are vaccinated prior to arrival in the destination country. (Korean J Pediatr Infect Dis 2012;19:89-110)

show abstract

“…2 Adolescents 15 years or older are more likely than infants and children to have meningococcemia without meningitis (40% vs 20%, respectively), shock at presentation (69% vs 27%, respectively), and a fatal outcome (22.5% vs 4.6%, respectively). 3 Not surprisingly then, adolescents have the highest case-fatality rate (estimated at ϳ20%) of any age group. Survivors at any age are at risk of permanent sequelae.…”

Section: Background Informationmentioning

confidence: 99%

Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients

2005

Pediatrics

View full text Add to dashboard Cite

Two peaks in the incidence of invasive meningococcal disease (IMD) occur in pediatric patients: infants younger than 1 year and adolescents 15 to 18 years of age. Although the incidence of IMD is highest in infants, the case-fatality rate is highest in adolescents (∼20%). Epidemiologic studies also have demonstrated increased risk of IMD among college freshman living in dormitories compared with other college students and similarly aged persons in the general population. At least 75% of cases of IMD in 11- to 18-year-olds are caused by serogroups A, C, Y, and W-135; thus, IMD potentially is preventable by immunization with quadrivalent meningococcal vaccines. Meningococcal A, C, Y, W-135 conjugate vaccine (MCV4) was licensed in 2005 for use in people 11 to 55 years of age. On the basis of data indicating increased risk of meningococcal disease and fatality among certain adolescents and college students, the American Academy of Pediatrics recommends administration of MCV4 to young adolescents (at the 11- to 12-year visit), students entering high school or 15-year-olds, and college freshmen who will be living in dormitories. For pediatric patients 11 years and older who are at increased risk of meningococcal disease, MCV4 also is recommended. The purposes of this statement are to provide the rationale for routine use of MCV4 in adolescents and to update recommendations for use of the meningococcal polysaccharide vaccine in pediatric patients.

show abstract

Invasive Meningococcal Disease in Adolescents and Young Adults

Abstract: Incidence of meningococcal infection in 15 through 24 year olds in Maryland increased and then declined during the 1990s. Infection in this age group was associated with an unusually high case-fatality ratio, and the vast majority of cases were potentially vaccine preventable.

Cited by 126 publications

References 26 publications

A Case of High Mortality, Treated with Multidisciplinary Approach in Intensive Care: Meningococcal Meningitis

A Case of High Mortality, Treated with Multidisciplinary Approach in Intensive Care: Meningococcal Meningitis

Meningococcal Disease and Quadrivalent MenACWY-CRM Vaccine (Menveo®)

Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients

Contact Info

Product

Resources

About